HIGHLIGHTS
- What: The approval of resmetirom marks a significant milestone in the treatment of MASH, offering a new pharmacological option for patients with moderate to advanced fibrosis [1].
- Who: Muhammad Mazhar Azam and colleagues from the Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan have published the Article: FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management, in the Journal: (JOURNAL)
SUMMARY
Globally, the prevalence of MASH stands at approximately 5%, however, in individuals with type 2 diabetes_mellitus (T2DM), the prevalence rises to about 37.3%, while among . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.